ストックスクリーナーアプリを入手
50.03
3.50%
1.69
アフターアワーズ：
49.26
-0.77
-1.54%
Alkermes Plc (ALKS) 最新ニュース
ALKS: Strong Q2 revenue, robust orexin pipeline progress, and LUMRYZ integration drive growth - TradingView
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down - Zacks Investment Research
Piper Sandler raises Alkermes stock price target on pipeline value - Investing.com
Alkermes Q2 Earnings Call Highlights - Yahoo Finance
Alkermes Q2 2026 slides: revenue surges 27% but acquisition costs squeeze - Investing.com
Earnings call transcript: Alkermes tops Q2 2026 estimates but shares fall premarket - Investing.com
ALKS Looks 64.8% Overvalued on GF Value™ - GuruFocus
Alkermes plc. Q2 2026: Revenue $496M, EPS $0— 10-Q Summary - TradingView
Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Avadel deal pushes Alkermes (NASDAQ: ALKS) to H1 2026 net loss - Stock Titan
Why is Alkermes stock sliding today? - Investing.com
Piper Sandler raises Alkermes stock price target on pipeline value By Investing.com - Investing.com Canada
Is Alkermes PLC (ALKS) Overvalued After Q2 Earnings Beat Expecta - GuruFocus
Alkermes affirms FY26 sales guidance of $1.730B-$1.840B - scanx.trade
ALKS Looks 64.8% Overvalued on GF Value™ as Insider Selling Pers - GuruFocus
Alkermes (ALKS) Reports Break-Even Earnings for Q2 - Yahoo Finance
Alkermes beats Q2 estimates, reaffirms revenue guidance - Investing.com
Earnings Flash (ALKS) Alkermes Public Company Posts Q2 EPS Breakeven, vs. FactSet Est of $0.03 Loss - marketscreener.com
Alkermes reports Q2 2026 revenue $496.0M, GAAP net income $0.5M, Adjusted EBITDA $139.2M - TradingView
Alkermes Q2 Revenue Rises to $496 Million as CEO Transition Nears - Quiver Quantitative
Alkermes plc Reports Second Quarter 2026 Financial Results - Yahoo Finance
Alkermes Plc (ALKS) Cash Flow - TradingKey
Alkermes Plc (ALKS) Institutional Confidence - TradingKey
Alkermes Plc (ALKS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alkermes Plc (ALKS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alkermes Plc (ALKS) Balance Sheet - TradingKey
Alkermes set to report earnings amid orexin frenzy and M&A buzz By Investing.com - Investing.com Australia
Alkermes set to report earnings amid orexin frenzy and M&A buzz - Investing.com UK
Alkermes Plc (ALKS) Income Statement - TradingKey
Alkermes Market Sentiment - Benzinga España
Alkermes Plc (ALKS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alkermes Plc (ALKS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alkermes Plc (ALKS) Stock Analysis: Robust Revenue Growth Amidst Strategic Expansion - DirectorsTalk Interviews
Alkermes plc (8AK) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout | AI
Alkermes plc (ALKS) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Interim Analysis: Sustained Wakefulness with Alixorexton in Narcolepsy - Sleep Review
Alkermes plc (ALKS) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (ALKS) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Alkermes Plc (ALKS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alkermes plc (ALKS) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (ALKS) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (ALKS) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (ALKS) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (ALKS) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (ALKS) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Stifel raises Alkermes stock price target on orexin program outlook By Investing.com - Investing.com South Africa
Stifel raises Alkermes stock price target on orexin program outlook - Investing.com
ALKS Upgraded by Stifel -- Price Target Raised to $63 - GuruFocus
(ALKS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Sustained Alixorexton Narcolepsy Data Could Be A Game Changer For Alkermes (ALKS) - simplywall.st
Alkermes to Report Second Quarter Financial Results on July 28, 2026 - Moomoo
Press Release: Alkermes to Report Second Quarter Financial Results on July 28, 2026 - Moomoo
Narcolepsy Treatments Are Advancing. Can Access? - Sleep Review
Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Study - Sahm
0.60%
0.34%
大文字化:
|
ボリューム (24 時間):